Form 4: Elanco Director Defers Fees into Stock Units

Elanco Animal Health Director Kapila K. Anand deferred cash retainer fees into 428.2522 deferred stock units, increasing her beneficial ownership to 8,513.6102 units.

Summary

• Kapila K. Anand, a Director of Elanco Animal Health Inc. (ELAN), acquired 428.2522 Deferred Stock Units (DSUs).
• This acquisition resulted from Ms. Anand's election to defer her director cash retainer fees under the Company's Directors' Deferral Plan.
• Each DSU is the economic equivalent of one share of Elanco common stock.
• The DSUs were issued at a price of $20.14 per unit, based on the closing price of Elanco common stock on September 30, 2025.
• The total value of the deferred compensation for this transaction is approximately $8,625.99.
• Following this transaction, Ms. Anand beneficially owns a total of 8,513.6102 Deferred Stock Units.
• The Deferred Stock Units will be settled in stock upon Ms. Anand's separation of service from the Company's Board of Directors.

Sentiment

Score: 7

Explanation: The transaction reflects a director's decision to increase equity alignment with the company, which is generally a positive signal for corporate governance and long-term commitment, though it is a routine compensation matter rather than a significant strategic event.

Positives

• Director Kapila K. Anand's decision to defer cash compensation into equity demonstrates alignment of her interests with those of long-term shareholders.
• The increase in beneficial ownership of Deferred Stock Units by a director signals confidence in the company's future performance.

Future Outlook

The Deferred Stock Units acquired by Ms. Anand will be settled in Elanco common stock upon her separation of service from the Company's Board of Directors, as per the Directors' Deferral Plan.

Industry Context

The deferral of director cash fees into equity is a common practice among publicly traded companies, particularly in the animal health and pharmaceutical sectors, to align the interests of board members with long-term shareholder value. This practice is generally viewed positively as it ties director compensation to the company's stock performance.

Comparison to Industry Standards

• This type of equity-based compensation for directors is standard across many industries, including healthcare and animal health, and is comparable to practices at companies like Zoetis Inc. (ZTS) or IDEXX Laboratories, Inc. (IDXX), where directors often have options to defer cash compensation into stock or receive equity grants.
• The specific mechanism of Deferred Stock Units (DSUs) that settle upon separation of service is a widely adopted corporate governance practice, ensuring directors maintain a vested interest in the company's performance throughout their tenure.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence due to director's enhanced equity alignment, suggesting a vested interest in long-term stock performance.
• Board of Directors: Reinforces the existing compensation structure that encourages equity ownership among directors.

Next Steps

• Settlement of the Deferred Stock Units in Elanco common stock upon Kapila K. Anand's separation of service from the Board of Directors.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned deferral of director compensation into equity, which is a positive for corporate governance and director alignment but does not introduce new material information that would warrant a change in investment recommendation. The transaction is expected and does not reflect a significant shift in company fundamentals or outlook.

Keywords

Elanco, ELAN, Form 4, Insider Transaction, Director Compensation, Deferred Stock Units, Equity Deferral, Corporate Governance